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Summary.-The influence of anaesthetics on the in vivo response of B16 melanoma
to melphalan was studied using an in vitro cell-survival assay. Three anaesthetics
were used, Saffan (Althesin) Sagatal (Nembutal) and Hypnorm. When Saffan was
administered to tumour-bearing animals before melphalan there was a significant
increase in tumour-cell kill. This effect was not observed with Sagatal or Hypnorm.
Maximum increase in tumour-cell kill was achieved when Saffan was administered
about 1 h before melphalan, and was dependent on Saffan dose.
Clonogenic tumour-cell repopulation after melphalan was rapid (TD= 1 day)
and the rate was similar from 2 levels of cell kill. When Saffan was combined with
melphalan the repopulation rate was the same as with melphalan alone, and the
increased cell kill was reflected in increased growth delay.
The in vitro response of B16 melanoma cells to melphalan was unaltered by pre-
treatment with, or simultaneous exposure to Saffan. The results suggest that the
mechanism of the enhanced cell kill in vivo is probably due to an indirect systemic
effect, rather than a direct effect on the tumour cells.
ANAESTHETICS are widely used in radio-
biological studies on small animals, and
sometimes in studies with cytotoxic drugs.
However, it is becoming apparent that the
use of anaesthetics for convenience is in-
advisable, since they can produce major
changes in blood pressure, tumour blood
flow and body temperature (Johnson
et al., 1976) and can influence the response
of normal and tumour tissue to cytotoxic
treatments (Bruce et al., 1970; Kaizer &
Van Putten, 1973; Garattini et al., 1974;
Fu & Phillips, 1976). In this paper we
describe the influence of several anaes-
thetics on the survival of B16 melanoma
tumour cells to in vivo treatments with
melphalan.
MATERIALS ANI) AIETHODS
Mice and tumnours.-Female C57BL mice
were obtained from the Institute of Cancer
Research breeding centre. They were used
when 8-10 weeks old, and weighed 18-25 g.
B16 melanoma was obtained from the
Roscoe B. Jackson Memorial Laboratory,
Bar Harbour, Maine, U.S.A., in 1970.
Tumours were transplanted s.c. into the
flanks of mice, using the brei technique de-
scribed by Stephens et al. (1977).
Anaesthetics.-A standard dose of each
anaesthetic was chosen such that the mice
remained unconscious for between 45 and
60 min. All anaesthetics were injected i.p.
and as soon as the mice became unconscious
they were transferred to an incubator at
35-36°C, which maintained their rectal
temperature at 37°C.
Saffan (the veterinary equivalent of Althe-
sin) was obtained from Glaxo Laboratories,
Brentford, Middlesex. Each ml contains 9 mg
alphaxalone (3a-hydroxy-5oa-pregnane-11,20-
dione) and 3 mg alphadalone acetate (21-
acetoxy - 30X- hydroxy - 5a - pregnane - 11,20-
dione). The standard dose used was 90 mg/kg.
Sagatal, the veterinary equivalent of Nem-
butal (pentobarbitone sodium) was obtained
from May and Baker Ltd, Dagenham,
Essex, and was used at a standard dose ofJ. H. PEACOCK AND T. C. STEPHENS
60 mg/kg. Hypnorm (fentanyl-fluanisone) a
veterinary neurolept-analgesic manufactured
by Janssen Pharmaceutica, Belgium, was
obtained from Crown Chemical Company
Ltd, Lamberhurst, Kent. The standard dose
used was 10-2 mg/kg.
Drugs.-L-phenylalanine mustard (mel-
phalan) was obtained from Burroughs Well-
come Ltd, Beckenham, Kent, in 100 mg
vials. It was dissolved in acid-ethanol (1 ml)
and the volume was made up to 10 ml with
buffered diluent (both supplied by the
manufacturers). For further dilutions PBS-
"A" (Dulbecco & Vogt, 1954) was used.
Preparation of cell suspensions.-Cell sus-
pensions were prepared as described pre-
viously (Stephens et at., 1977). The mean cell
yield per gram of tissue trypsinized for
untreated tumours was 9-9 x 107 (s.d. 2-5 x
107, n = 23). Vital staining with trypan
blue indicated viability > 95%.
In vitro cell-survival assays.-Survival of
B16 melanoma cells was measured using the
soft-agar assay first described by Courtenay
(1976) and modified by Stephens et at. (1977).
Viable cells varying in number from 500 to
2 x 104 were plated into 30 mm Petri
dishes and the total cell number per dish was
kept at 104 by the addition of cells killed
by irradiation (200 Gy). The culture medium
used was Ham's F12 supplemented with 20%
foetal calf serum (both supplied by Flow
Laboratories Ltd, Irvine, Scotland). Cultures
were incubated for 14-16 days at 37°C in a
water-saturated atmosphere of 5% 02, 5%
C02 in N2-
Colonies ofmore than 50 cells were counted
in at least 3 dishes per experimental point.
The plating efficiency (PE) was calculated
as the mean number of colonies per dish
divided by the number of cells plated.
The mean PE of untreated B16 melanoma
cells in this series of experiments was 0 47
(s.d. 0-16, n = 23). PEs as low as 0 0005
could be measured by this method. The cell
kill in treated tumours was expressed either
as surviving fraction (SF = PE treated/PE
control) or as fraction of surviving cells per
tumour (= SF x relative cell yield per
gram x relative tumour weight). The former
takes account only of changes in the colony-
forming ability of the cells, whilst the latter
also allows for changes in tumour size and
cell yield.
In vitro drug treatment.-Cell suspensions
of untreated tumours were prepared as
described above, and the cells suspended in
Ham's F12 culture medium. Drugs were
added to the suspensions, and after 1 h of
exposure the suspensions were centrifuged,
the pellet washed and resuspended in fresh
medium. Cell survival was measured in the
soft-agar assay.
RESULTS
Influence of anaesthetics on melphalan
dose-survival curve
The dose-response curve of B16 mela-
noma to melphalan in conscious animals
is shown in Fig. 1 (closed symbols).
Assays were performed 18 h after treat-
ment. The relationship between dose of
melphalan and fraction of surviving cells
per tumour is exponential, with a Djo
(the dose required to reduce cell survival
to 10% of the control value) of 8 mg/kg.
Also showninFig. 1 is thesurvival curve
for animals anaesthetized with Saffan
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FIG. 1.-Dose-survival curves for B16 mela-
noma treated with melphalan either in con-
scious mice (0) or in mice anaesthetized
with Saffan 20 min earlier (0).
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FIG. 2.-Dose-survival curve for B16 mela-
noma treated with melphalan either in
Sagatal - anaesthetized mice (A) or
Hypnorm-sedated mice (A). The solid line
represents melphalan alone and the hatched
line represents Saffan and melphalan, both
from Fig. 1.
(90 mg/kg) 20 min before receiving mel-
phalan (open symbols). Saffan alone had
no effect upon the fraction of surviving
cells per tumour, but did enhance the
cell kill achieved with melphalan. The
dose-response curve was again exponen-
tial but the D1o was reduced to 4 mg/kg.
Fig. 2 shows the effect on the melphalan
response curve of anaesthetizing animals
with either Sagatal (closed symbols)
or Hypnorm (open symbols) administered
20 min before melphalan. The solid line
indicates the melphalan-alone curve and
the broken line represents the Saffan +
melphalan curve from Fig. 1. Pretreat-
ment with these anaesthetics did not alter
the tumour-cell kill with melphalan alone.
Effect ofSaffan dose
Saffan was administered to tumour-
bearing mice at various doses 20 min
before melphalan (7.5 mg/kg). The dose-
response curve is shown in Fig. 3. There
is an enhanced effect, even at the lowest
dose of Saffan (15 mg/kg), although this
did not render the animals unconscious.
At higher doses there is a further decrease
in the number of surviving cells per
tumour.
Timing ofSaffan administration
Saffan (90 mg/kg) was administered at
various times from 6 h before to 2 h after
melphalan (7.5 mg/kg) and the results are
shown in Fig. 4. In conscious animals this
dose reduced survival to 10% of the
control. Maximum enhancement of mel-
phalan cytotoxicity was achieved when
Saffan was administered shortly before
melphalan. Anaesthesia at this time ap-
proximately doubled the log kill oftumour
cells due to melphalan alone.
When Saffan was given earlier, the
degree of enhancement gradually fell
andby 6h no significant enhancement was
apparent. Since animals only remained
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Fiuc. 4. Cell survival in B16 melanoma after
treatment with Saffan (90 mg/kg) at var-
ious times before or after melphalan at
7-5 mg/kg (0). Melphalan alone (0).
unconscious for 45-60 min after this dose
of Saffan, it seems that there was some
enhancement even when melphalan was
administered to mice which had regained
consciousness. There was no enhanced
cytotoxicity when Saffan was adminis-
tered at times ranging from a few minutes
to 3 h after melphalan.
Duration of melphalan cytotoxicity
Melphalan (7.5 mg/kg) was adminis-
tered both to conscious animals and to
animals anaesthetized with Saffan (90
mg/kg) 20 min earlier. Assays of cell
survival were performed at various times
later, and the results are shown in Fig. 5.
Although there is considerable scatter in
these data, the fitted lines suggest that in
Saffan-pretreated mice the duration of
melphalan cytotoxicity was increased by
a factor ofabout 2. In both curves survival
fell to a minimum and remained at that
level for 24 h, suggesting that repair of
melphalan damage does not occur.
Repopulation studies
The repopulation of B16 melanoma
treated with melphalan alone and in
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FIG. 5. Time-response curves for B16
melanoma treated with melphalan (7-5
mg/kg) alone (-), or with Saffan (90 mg/
kg) administered 20 min before melphalan
at 7-5 mg/kg ( ).
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combination with Saffan was examined by
performing sequential cell-survival as-
says at various times after treatment.
The growth of untreated tumours was
not significantly different from that des-
cribed previously (Stephens & Peacock,
1977). Tumour weight, total cells per
tumour (tumour weight x cell yield per
gram) and clonogenic cells per tumour
(total cells per tumour x PE) all in-
creased with a doubling time (TD) of 3
days.
After treatment with melphalan at
7*5 mg/kg in unanaesthetized mice (Fig.
6a) tumour weight and total cells per
tumour continued to increase, but with a
TD of 3-5 days. Clonogenic cells per
tumour were reduced by about one
decade to 1-5 x 105, and repopulation
started immediately with a TD of 1 day.
After 15 mg/kg of melphalan, also in
unanaesthetized mice (Fig. 6b), there was
a greater reduction in the tumour growth
(TD= 5 days) than at the lower dose.
Total cells per tumour decreased in the
first 3 days after treatment from ' 107
to 3 x 106, and then recovered with a
TD of 5 days. The total clonogenic cell
number was reduced from 5 x 106 to
5 X 103 within 2 h of treatment. Re-
;
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FIG. 6. Cell repopulation curves for B16 melanoma treated with: (a) melphalan at 7-5 mg/kg,
(b) melphalan at 15 mg/kg, and (c) Saffan (90 mg/kg) 20 min before melphalan at 7-5 mg/kg.
population began immediately with a
TD of 0O8 days, until between Days 7 and
8, when the rate slowed to a TD of about
5 days, corresponding with that of the
tumour weight and total cells per tumour.
When the lower dose of melphalan
(7.5 mg/kg) was given to animals treated
20 min earlier with Saffan at 90 mg/kg
(Fig. 6c), the initial cell kill and the pattern
of repopulation were similar to those
observed with the higher dose of melpha-
lan alone (15 mg/kg).
Influence of Saffan on melphalan dose-
survival curve in vitro
B16 melanoma cells were exposed in
vitro to various doses of melphalan from
0 5 to 5 ,ug/ml (Fig. 7). Melphalan at
5 ,ug/ml produced 3 decades of cell kill.
Cells were treated with Saffan (120 ,ug/ml)
for I h, either immediately before or
simultaneously with melphalan, but this
did not increase the kill compared with
melphalan alone. One hour's incubation of
cells with this dose of Saffan alone did
not change the PE.
DISCUSSION
We have investigated the cytotoxic ef-
fects of melphalan in B16 melanoma,
and have shown that enhanced cell kill
occurs in animals which have been
recently treated with the steroid anaes-
thetic Saffan. Anaesthesia per se did not
appear to be essential, since some en-
hancement was seen with sub-anaes-
thetic doses of Saffan, and when melpha-
lan was administered after the animals
had regained consciousness after Saffan
anaesthesia. No enhanced cell kill was
seen when melphalan was administered
to mice anaesthetized with Sagatal (a
barbiturate hypnotic) or sedated with
Hypnorm (a combined neuroleptic/anal-
gesic). At concentrations estimated to be
higher than would occur in animals,
Saffan did not enhance the kill of B16
melanoma tumour cells by melphalan
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melanoma cells treated with mel]
alone (a), Saffan (120,ug/ml) folloxA
melphalan (A) and Saffan (120 jtg/rr
melphalan administered simultan
(0).
in vitro, implying that the agent
directly affect cell sensitivity to
lan.
The data in Fig. 5 suggest tU
could be a doubling of the du]
melphalan cytotoxicity in Saffan-
ed mice, and direct measuren
serum levels would be required
firm this. A comparison of the pc
melphalan in vivo and in vitro
that it does not undergo any si
activation in vivo, so we can
rule out altered activation of m
in Saffan-pretreated mice, and it
likely that a reduced rate of m
clearance was responsible for the
increase in cytotoxicity. There
either slower metabolism to
products, or a reduction in the
excretion of the parent compou
duced body temperature is unlik
involved, since mice were maint
3700 by external heating when uncon-
scious and during recovery.
The repopulation studies were per-
formed to establish whether the enhanced
cell kill achieved with melphalan + Saffan
also led to enhanced growth delay, but
they also allow a comparison of the
repopulation after melphalan, with the
repopulation patterns reported previously
in the B16 melanoma for cyclophospha-
\ mide and CCNU (Stephens & Peacock,
1977). Our data suggest that Saffan was
simply dose-modifying to melphalan, and
o that it enhanced growth delay when the
agents were combined.
In our previous study we found that
* repopulation after CCNU was much faster
than after cyclophosphamide. We have
now shown that after treatment with
4 5 melphalan, repopulation was similar to
that after CCNU. We have also shown
of B16 that the repopulation rate was not signi-
phalan ficantly different at 2 different levels of
i)and melphalan cell kill.
eously Whether there is any therapeutic ad-
vantage to be gained in tumour chemo-
therapy by combining the steroid Saffan
with melphalan is not yet clear. In clinical
chemotherapyothersteroids, notablypred-
t did not nisone and prednisolone, are often in-
melpha- cluded in regimes with melphalan. Experi-
mentally, Wilkinson & Harrap (1978)
iat there have found increased antitumour effect
ration of when melphalan and prednisolone were
pretreat- combined. However, they also showed
nents of increased host toxicity due to the com-
to con- bination, and with melphalan + Saffan,
)tency of Dr M. Y. Gordon (personal communica-
suggests tion) has shown enhanced cell kill in mouse
ignificant marrow cells (ADC-Cs) similar to that
probably observed in B16 melanoma.
Lelphalan The results show clearly that Saffan
is more anaesthesia markedly alters the response
Lelphalan of both tumour and normal tissue to at
observed least one cytotoxic treatment. Together
may be with the work of others referred to above,
inactive our results stress the importance of
rate of including appropriate controls in all
mnd. Re- experiments, and reinforce the current
ely to be trend of avoiding anaesthetics whenever
;ained at possible.
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